IGMS Stock Overview
A clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IGM Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.47 |
| 52 Week High | US$22.50 |
| 52 Week Low | US$4.72 |
| Beta | 0.19 |
| 11 Month Change | -33.17% |
| 3 Month Change | 3.50% |
| 1 Year Change | 57.57% |
| 33 Year Change | -82.45% |
| 5 Year Change | -52.79% |
| Change since IPO | -61.03% |
Recent News & Updates
Recent updates
We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Oct 08
IGM Biosciences: Waiting For Godot
Sep 18IGM Biosciences: Unlikely To Move The Needle Again In 2024
May 12Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?
Apr 28IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Feb 12We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25Shareholder Returns
| IGMS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -27.3% | -10.9% | -2.2% |
| 1Y | 57.6% | 13.9% | 30.1% |
Return vs Industry: IGMS exceeded the US Biotechs industry which returned 20.8% over the past year.
Return vs Market: IGMS exceeded the US Market which returned 32.3% over the past year.
Price Volatility
| IGMS volatility | |
|---|---|
| IGMS Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IGMS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IGMS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 198 | Mary Harler | igmbio.com |
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.
IGM Biosciences, Inc. Fundamentals Summary
| IGMS fundamental statistics | |
|---|---|
| Market cap | US$600.59m |
| Earnings (TTM) | -US$219.84m |
| Revenue (TTM) | US$2.92m |
193.0x
P/S Ratio-2.6x
P/E RatioIs IGMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IGMS income statement (TTM) | |
|---|---|
| Revenue | US$2.92m |
| Cost of Revenue | US$184.38m |
| Gross Profit | -US$181.46m |
| Other Expenses | US$38.38m |
| Earnings | -US$219.84m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.70 |
| Gross Margin | -6,218.71% |
| Net Profit Margin | -7,534.03% |
| Debt/Equity Ratio | 0% |
How did IGMS perform over the long term?
See historical performance and comparison